IPF COMFORT Study for Chronic Cough

 

Trial Objective

The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis. The investigational drug the study is testing is a once a day tablet called orvepitant. The cough in IPF may be caused by the airways becoming oversensitive, and it is hoped that orvepitant will reduce this over-sensitivity.
The purpose of the IPF COMFORT Study is to see if orvepitant reduces the severity and burden of coughing in people with IPF. The study will also test the safety of orvepitant, how the drug is absorbed and used within the body. Orvepitant is an investigational medicine. This means that it is not approved for sale, but it is but it is approved for use in clinical studies like this one.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

People ages 40 and older who have been diagnosed with Idiopathic Pulmonary Fibrosis and have had a troublesome cough lasting for at least 8 weeks that has not responded to other treatments

Age: 40+    Gender: Any Gender


Estimated Time Commitment

Six study appointments over 17 weeks, with clinic visits every three to four weeks



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kaitlin Fier
303.270.2852    

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Additional Resources

Trial Sponsors

NeRRe Therapeutics Ltd


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: